{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hu Y"],"funding":["Chinese Preventive Medicine Association Vaccine and Immunization Youth Talent Promotion Project","National Natural Science Foundation of China","the state key laboratory of infection disease prevention and control grant","State Key Laboratory of Infection Disease Prevention and Control"],"pagination":["272"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11054858"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(4)"],"pubmed_abstract":["Since November 2021, Omicron has emerged as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, and its sublineages continue to appear one after another, significantly reducing the effectiveness of existing therapeutic neutralizing antibodies (NAbs). It is urgent to develop effective NAbs against circulating Omicron variants. Here, we isolated receptor binding domain (RBD)-specific single memory B cells via flow cytometry from a COVID-19 convalescent. The antibody variable region genes of the heavy chain (VHs) and light chain (VLs) were amplified and cloned into expression vectors. After antibody expression, ELISA screening and neutralizing activity detection, we obtained an IGHV3-53-encoded RBD-targeting cross-neutralizing antibody D6, whose VL originated fr"],"journal":["Pathogens (Basel, Switzerland)"],"pubmed_title":["Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent."],"pmcid":["PMC11054858"],"funding_grant_id":["U20A20362,92369103","CPMAQT_YM0301","2020SKLID102","U20A20362, 92369103"],"pubmed_authors":["Liu Y","Hu C","Hu Y","Ren L","Li D","Shao Y","Liang H","Wang S","Hao Y","Su J","Zhu B","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent.","description":"Since November 2021, Omicron has emerged as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, and its sublineages continue to appear one after another, significantly reducing the effectiveness of existing therapeutic neutralizing antibodies (NAbs). It is urgent to develop effective NAbs against circulating Omicron variants. Here, we isolated receptor binding domain (RBD)-specific single memory B cells via flow cytometry from a COVID-19 convalescent. The antibody variable region genes of the heavy chain (VHs) and light chain (VLs) were amplified and cloned into expression vectors. After antibody expression, ELISA screening and neutralizing activity detection, we obtained an IGHV3-53-encoded RBD-targeting cross-neutralizing antibody D6, whose VL originated fr","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-05-25T03:08:07.545Z","creation":"2026-05-25T03:06:55.608Z"},"accession":"S-EPMC11054858","cross_references":{"pubmed":["38668227"],"doi":["10.3390/pathogens13040272"]}}